OIS@AAO 2016 Videos

Vicken Karageozian, MD, president and chief medical officer, Allegro Ophthalmics, shares how Allegro has “taken a lot of risk out of the equation” after reporting…

Kevin Waltz, MD, partner, Eye Surgeons of Indiana, Mynosys, explains how the company’s Zepto device helps create the “round, consistent” anterior lens capsulotomy in nearly…

Bill Burns, president and CEO, Encore Vision, introduces OIS to Encore Vision, which has the “sole purpose” of developing a treatment for presbyopia. Burns says…

Joseph Boorady, president and CEO, TearScience, shares details on recent studies that demonstrated LipiFlow’s ability to deliver long-term relief for dry eye sufferers. He also…

Bernhard Günther, managing director and co-founder, Novaliq GmbH, tells OIS-TV about Novaliq’s new CEO, Christian Roesky, PhD. Günther will assume the role of chief innovation…

Megan Baldwin, PhD, CEO and managing director, Opthea Ltd., introduces OPT-302, a new vehicle for targeting the VEGF pathway and wet age-related macular degeneration (AMD).…

Jim Mazzo, global president of ophthalmic devices, Carl Zeiss Meditec, explains why ophthalmology continues to draw interest from new players. He also reveals how he’s…

John Kilcoyne, president and CEO, ReVision Optics, shares the company’s plans for a commercial rollout of Raindrop, the firm’s promising corneal inlay. Participant: John Kilcoyne…

Amar Sawhney, president, CEO, and chairman of Ocular Therapeutix, gives details on his company’s new collaboration with Regeneron to develop a sustained-release formulation of the…

Vince Anido, PhD, CEO and chairman, Aerie Pharmaceuticals, sees hopeful signs in the FDA’s process to review combination therapies. This positioning could benefit Aerie in…

The IPO market in ophthalmology may have cooled off last year, but that only mirrored what’s happened in healthcare overall. In this video from OIS@AAO…

Jonathan Norris, managing director at Silicon Valley Bank, delivered his overview of private investing in health care in 2016. Among the high points: Investments in…